A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 Dec 2017 Status changed from recruiting to discontinued.
- 18 Sep 2017 Planned End Date changed from 27 Jul 2018 to 28 Sep 2018.
- 18 Sep 2017 Planned primary completion date changed from 27 Jul 2018 to 28 Sep 2018.